You are here

Novel sanitizer/disinfectants against viral infections with long-lasting effect

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42AI124738-02
Agency Tracking Number: R42AI124738
Amount: $1,359,020.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA18-575
Timeline
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2018-12-01
Award End Date (Contract End Date): 2020-11-30
Small Business Information
1120 15TH ST CA 2151
Augusta, GA 30912-0004
United States
DUNS: 968429386
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 STEPHEN HSU
 (706) 721-4816
 shsu@augusta.edu
Business Contact
 STEPHEN HSU
Phone: (706) 721-4816
Email: shsu@augusta.edu
Research Institution
 AUGUSTA UNIVERSITY
 
1120 15TH STREET
AUGUSTA, GA 30912-0004
United States

 Nonprofit college or university
Abstract

AbstractNorovirus is the most common cause of acute gastroenteritis in the United States,
associated annually with 19-21 million illnesses, 56,000-71,000 hospitalizations and 570-800
deaths (US CDC, Overview about Norovirus). Norovirus is one of the nonenveloped viruses that
are resistant to alcohol sanitization. According to US CDC Guidelines for the Prevention and
Control of Norovirus Gastroenteritis Outbreaks in Healthcare Settings, the primary method for
prevention of norovirus transmission by hand is hand wash with soap and water. However, this
method does not inactivate norovirus, but rather releases and washes the virus off the skin.
Currently available agents that are able to inactivate norovirus are toxic to human cells. In fact,
viral outbreaks worldwide are on the rise despite the increased effort to prevent them. Our goal
is to develop several effective, non-toxic, environment-friendly hand sanitizer/surface
disinfectants to aid in the prevention of viral outbreaks, particularly norovirus prevention. During
Phase I of the STTR project, we focused on testing the proof-of-concept that novel sanitizer
formulations (ProtecTeaV) containing EGCG-palmitate are capable of inactivating norovirus and
bacteria. We have successfully identified ProtecTeaV formulations with virucidal activity and this
activity persists on a clean surface beyond a 12-hour period. The new findings have been published
in the International Journal of Microbiology andamp; Infectious Diseases (Widjaja et al, 2018). The
objectives of our Phase II proposal include optimization and finalization of the ProtecTeaV
formulation in several prototypes; testing these prototypes and receiving approval from
regulatory agencies; and conversion of the prototypes to large scale production-ready products.
The Randamp;D effort will continue to be based on the existing strong partnership between Camellix and
Augusta University, our current manufacturer partner, and experts in formulation, regulatory,
production, and business development. We expect to launch the first ProtecTeaV product at the
completion of this project.Project Narrative
Currently used alcohol-based hand sanitizers are ineffective against nonenveloped
viruses such as norovirus (the most common cause of gastroenteritis), and the
effectiveness of alcohol only lasts for less than 20 seconds. Based on patented technology,
we have identified an effective, non-toxic, environment-friendly, and long-lasting
sanitizer formulation against norovirus. In the Phase II proposal, we will optimize and
finalize the formulation to produce several prototypes for regulatory approval and
prepare to scale-up for mass production.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government